WASHINGTON -- (Business Wire)
The law firm of Finkelstein Thompson LLP is investigating potential
claims on behalf of shareholders of Omnicare, Inc. (“Omnicare” or the
“Company”) (NYSE: OCR), concerning the Company’s proposed acquisition by
CVS Health Corporation. Under the terms of the proposal, Omnicare
shareholders will receive $98.00 in cash for each share of Omnicare
common stock they own. At least one analyst has set a high target price
of $104.00 for Omnicare shares. The entire transaction is valued at
approximately $12.7 billion.
The investigation is focused on whether Omnicare’s Board of Directors
breached its fiduciary duty in failing to maximize consideration to
shareholders, the potential unfairness of the consideration to
shareholders, the process by which the Board of Directors considered the
transaction, and potential conflicts of interest among Omnicare’s Board
of Directors’ members.
If you are interested in discussing your rights as an Omnicare
shareholder, or have information relating to this investigation, please
contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050
or (202) 337-8000, or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
financial litigation, and has been appointed as lead or co-counsel in
dozens of shareholder class actions. Indeed, the firm has served in
leadership roles in cases that have recovered over $1 billion for
investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our website
at www.finkelsteinthompson.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150522005552/en/
Contacts:
Finkelstein Thompson LLP
Rosalee B. C. Thomas, 877-337-1050
rbcthomas@finkelsteinthompson.com
Source: Finkelstein Thompson LLP
© 2024 Canjex Publishing Ltd. All rights reserved.